Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease that is not well understood. Therapy for COPD is often started late, while triple therapy or inhaled corticosteroid (ICS)-containing regimens are used inappropriately in some patients.
Mild cases are estimated to comprise over half of the overall asthma population. Unlike in most other chronic conditions, patients with mild asthma are still at risk of serious outcomes, including death, according to Professor Helen Reddel of the Woolcock Institute of Medical Research, University of Sydney, who spoke at the Advances in Medicine 2020 virtual conference. [Eur Respir J 2007;30:403-406; Can Respir J 2010;17:74-80; Royal College of Physicians. Why asthma still kills: National Review of Asthma Deaths Confidential Enquiry Report. London, 2014]
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
Treatment with intravenous (IV) dexamethasone for 10 days significantly reduces duration of mechanical ventilation at 28 days and 60-day mortality in patients with established moderate-to-severe acute respiratory disease syndrome (ARDS) compared with no dexamethasone, results of the DEXA-ARDS trial have shown.